Skip to main content
SpringerLink
Log in

Management of skin toxicity of epidermal growth factor receptor inhibitors

  • Day-to-Day Practice
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

Epidermal growth factor receptor (EGFR)-targeted therapies (monoclonal antibodies such as cetuximab and panitumumab as well as tyrosine kinase inhibitors like erlotinib and gefitinib) are responsible for a unique constellation of mechanism-based, class-specific side effects on the skin. Besides the well-known acneiform eruption, this skin toxicity consists of xerosis (leading to eczema and fissures), paronychia, hair changes, telangiectasia, hyperpigmentation, and mucosal changes. Dermatologic treatment is supportive and aims at maintaining quality of life while continuing EGFR-inhibitor therapy. Although a recent study demonstrated the effectiveness of prophylactic minocycline in cetuximab-induced acneiform eruption, randomized controlled trials remain sparse and evidence-based guidelines are lacking. Based on personal experience, most cases of acneiform eruption are well controlled by topical metronidazole and oral minocycline 100 mg qd. For severe reactions, minocycline dose is doubled and saline compresses have proven very valuable. For superinfection with Staphylococcus aureus, oral cefuroxim axetil can be added for a short term. Emollients and topical steroids can be administered for skin dryness or eczema. Paronychia is the hardest part to treat but antiseptic soaks and a corticosteroid paste can alleviate symptoms to some degree.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Johnston JB, Navaratnam S, Pitz MW et al (2006) Targeting the EGFR pathway for cancer therapy. Curr Med Chem 13:3483–3492

    Article  PubMed  CAS  Google Scholar 

  2. Busam KJ, Capodieci P, Motzer R et al (2001) Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144:1169–1176

    Article  PubMed  CAS  Google Scholar 

  3. Segaert S, Van Cutsem E (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16:1425–1433

    Article  PubMed  CAS  Google Scholar 

  4. Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6:803–812

    Article  PubMed  CAS  Google Scholar 

  5. Melichar B, Nemcova I (2007) Eye complications of cetuximab therapy. Eur J Cancer Care 16:439–443

    Article  CAS  Google Scholar 

  6. Perez-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining? J Clin Oncol 23:5235–5246

    Article  PubMed  Google Scholar 

  7. Van Cutsem E (2006) Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 11:1010–1017

    Article  PubMed  Google Scholar 

  8. http://ctep.cancer.gov/forms/CTCAEv3.pdf

  9. Segaert S, Tabernero J, Chosidow O et al (2005) The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 3:599–606

    Article  PubMed  Google Scholar 

  10. Hetherington J, Andrews C, Vaynshteyn Y et al (2007) Managing follicular rash related to chemotherapy and monoclonal antibodies. Community Oncol 4:157–162

    Google Scholar 

  11. Segaert S, Van Cutsem E (2007) Clinical management of EGFRI dermatologic toxicities: the Europe perspective. Oncology 5(Suppl 11):22–26

    Google Scholar 

  12. Jatoi A, Rowland K, Sloan JA et al (2008) Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes. Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 113:847–853

    Article  PubMed  CAS  Google Scholar 

  13. Scope A, Agero ALC, Dusza SW et al (2007) Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 25:5390–5396

    Article  PubMed  CAS  Google Scholar 

  14. Robert C, Soria J-C, Spatz A et al (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6:491–500

    Article  PubMed  CAS  Google Scholar 

  15. Lacouture ME, Basti S, Patel J et al (2006) The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol 4:236–238

    PubMed  Google Scholar 

  16. Guillot B, Bessis D (2006) Aspects cliniques et prise en charge des effets secondaires cutanés des inhibiteurs du récepteur à l’EGF. Ann Dermatol Venereol 133:1017–1020

    Article  PubMed  CAS  Google Scholar 

  17. Gutzmer R, Werfel T, Kapp A et al (2006) Kutane Nebenwirkungen einer EGF-Receptor-Blockade und deren management. Hautarzt 57:509–513

    Article  PubMed  CAS  Google Scholar 

  18. Galimont-Collen AFS, Vos LE, Lavrijsen APM et al (2007) Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 43:845–851

    Article  PubMed  CAS  Google Scholar 

  19. Monti M, Motta S (2007) Clinical management of cutaneous toxicity of anti-EGFR-agents. Int J Biol Markers 22:S53–S61

    PubMed  CAS  Google Scholar 

  20. Perez-Soler R, Delord JP, Halpern A et al (2005) HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 10:345–356

    Article  PubMed  CAS  Google Scholar 

  21. Lynch TJ, Kim ES, Eaby B et al (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12:610–621

    Article  PubMed  CAS  Google Scholar 

  22. Luu M, Lai SE, Patel J et al (2007) Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. Photodermatol Photoimmunol Photomed 23:42–45

    Article  PubMed  Google Scholar 

  23. Bernier J, Bonner J, Vermorken J et al (2008) Consensus guidelines for the management of radiation dermatitis and co-existing acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 19:142–149

    Article  PubMed  CAS  Google Scholar 

  24. Plewig G, Kligman AM (2000) (eds) Acne and rosacea, 3d ed. Springer-Verlag, Berlin.

  25. Perez-Soler R (2006) Topical vitamin K3 (menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin (abstract). J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part 1 24:3036

    Google Scholar 

  26. Suh K-Y, Kindler HL, Medenica M et al (2006) Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br J Dermatol 154:191–192

    Article  Google Scholar 

Download references

Conflict of interest statement

No funds were received in support of this study. The author has been a paid speaker for Merck-Serono, Amgen and Roche.

Author information

Authors and Affiliations

  1. Department of Dermatology, University Hospital Sint-Rafaël, Kapucijnenvoer 33, B-3000, Leuven, Belgium

    Siegfried Segaert

Authors
  1. Siegfried Segaert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Siegfried Segaert.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Segaert, S. Management of skin toxicity of epidermal growth factor receptor inhibitors. Targ Oncol 3, 245–251 (2008). https://doi.org/10.1007/s11523-008-0092-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-008-0092-7

Keywords

Search

Navigation